-
Hagemann TL. (2022). Alexander disease: models, mechanisms, and medicine. Current Opinion in Neurobiology, 72, 140-147.
[excellent short review on basic mechanisms of disease] [free full text until Jan 12] -
Hagemann TL, Powers B, Lin N-H, Mohamed AF, Dague KL, Hannah SC, Bachmann G, Mazur C, Rigo F, Olsen AL, Feany MB, Perng M-D, Berman RF, Messing A. (2021). Antisense therapy in a rat model of Alexander disease reverses GFAP pathology, white matter deficits, and motor impairment. Science Translational Medicine. 13, eabg4711
[first animal model with myelin deficits, also with obvious clinical symptoms]
Free access: https://www.science.org/stoken/author-tokens/ST-178/full -
Brenner M, Messing A. (2021). Regulation of GFAP expression. ASN Neuro. 13, 1-32. [comprehensive review, focusing on transcription] [full text]
-
Messing A, Brenner M. (2020). GFAP at 50. ASN Neuro 12, 1759091420949680. [comprehensive review on (nearly) all aspects of GFAP] [full text]
-
Helman G, Takanohashi A, Hagemann TL, Perng MD, Walkiewicz M, Woidill S, Sase S, Cross Z, Du Y, Zhao L, Waldman A, Haake BC, Fatemi A, Brenner M, Sherbini O, Messing A, Vanderver A. Simons C. (2020). Type II Alexander disease caused by splicing errors and aberrant overexpression of a GFAP isoform. Human Mutation 41, 1131-1137. [two very unusual variants, one without even an amino acid change – note that patient #2 was previously reported as #43 in Li et al. 2005, where he was described as not having an identifiable variant]
-
Messing A. (2019). Refining the concept of GFAP toxicity in Alexander disease. Journal of Neurodevelopmental Disorders 11, 27. [full text] [short review]
-
Messing A. (2018). Alexander disease. Handbook of Clinical Neurology, 148, 693-700. [concise review of clinical genetics]
-
Jones JR, Kong L, Hanna I, M. G., Hoffmann B, Krencik R, Bradley R, Hagemann T, Choi J, Doers M, Dubovis M, Sherafat MA, Bhattacharyya A, Kendziorski C, Audhya A, Messing A, Zhang SC. (2018). Mutations in GFAP disrupt the distribution and function of organelles in human astrocytes. Cell Reports, 25, 947-958 [full text]
-
Wang L, Xia J, Li J, Hagemann TL, Jones JR, Fraenkel E, Weitz DA, Zhang SC, Messing A, Feany MB. (2018). Tissue and cellular rigidity and mechanosensitive signaling activation in Alexander disease. Nature Communications, 9, 1899. [full text]
-
Hagemann TL, Powers B, Mazur C, Kim A, Wheeler S, Hung G, Swayze E, Messing A. (2018) Antisense suppression of glial fibrillary acidic protein as a treatment for Alexander disease. Annals of Neurology, 83, 27-39. [first real prospect for treatment] [full text]
-
Moody LR, Barret-Wilt GA, Sussman MR, Messing A. (2017). Glial fibrillary acidic protein exhibits altered turnover kinetics in a mouse model of Alexander disease. Journal of Biological Chemistry, 292, 5814-5824
-
Wang L, Hagemann TL, Messing A, Feany MB (2016). An in vivo pharmacological screen identifies cholinergic signaling as a therapeutic target in glial-based nervous system disease. Journal of Neuroscience, 36, 1445-1455
-
Wang L, Hagemann TL, Kalwa H, Michel T, Messing A, Feany MB. (2015). Nitric oxide mediates glia-induced neurodegeneration in Alexander disease. Nature Communications, 6, 6:8966 | DOI: 10.1038/ncomms9966. [full text]
-
Jany PL, Agosta GE, Benko WS, Eickhoff JC, Keller SR, Köehler W, Koeller D, Mar S, Naidu S, Ness JM, Pareyson D, Renaud DL, Salsano E, Schiffmann R, Simon J, Vanderver A, Eichler F, van der Knaap MS, Messing A. (2015). CSF and blood levels of GFAP in Alexander disease. eNeuro, 2(5). DOI: 10.1523/ENEURO.0080-15.2015. [full text]
-
LaPash Daniels CM, Paffenroth E, Austin EV, Glebov K, Lewis D, Walter J, Messing A. (2015). Lithium decreases glial fibrillary acidic protein in a mouse model of Alexander disease. PLoS One, 10(9), e0138132. https://doi.org/10.1371/journal.pone.0138132.
-
Walker AK*, LaPash Daniels CM*, Goldman JE, Trojanowski JQ, Lee VMY, Messing A. (2014). Astrocytic TDP-43 pathology in Alexander disease. Journal of Neuroscience, 34, 6448-6558 (* joint first authors)
-
Hagemann TL, Paylor R, Messing A. (2013). Deficits in adult neurogenesis, contextual fear conditioning and spatial learning in a Gfap mutant mouse model of Alexander disease. Journal of Neuroscience, 33, 18698-18706. [describes an entirely new phenotype not previously known to be part of the disease]
-
Jany, P.L., Hagemann, T.L., and Messing, A. (2013). GFAP expression as an indicator of disease severity in mouse models of Alexander disease. ASN Neuro 5:art:e00109.doi:10.1042/AN20130003. [link to full article and podcast]
-
Cunningham, R., Jany, P., Messing, A., and Li, L. (2013). Protein changes in immunodepleted cerebrospinal fluid from transgenic mouse models of Alexander disease detected using mass spectrometry. Journal of Proteome Research, 12, 719-728.
-
LaPash Daniels CM, Austin EV, Rockney DE, Jacka EM, Hagemann TL, Johnson DA, Johnson JA, Messing A. (2012) Beneficial effects of Nrf2 overexpression in a mouse model of Alexander disease. Journal of Neuroscience, 32, 10507-10515. [link to full article]
-
Hagemann TL, Jobe EM, Messing A. (2012) Genetic ablation of Nrf2/antioxidant response pathway in Alexander disease mice reduces hippocampal gliosis but does not impact survival. PLoS ONE, 7, e37304. [link to full article]
-
Flint D, Li R, Webster LS, Naidu S, Kolodny E, Percy A, van der Knaap M, Powers JM, Mantovani JF, Ekstein J, Goldman JE, Messing A, Brenner M. (2012). Splice site, frameshift and chimeric GFAP mutations in Alexander disease. Human Mutation, 11:1141-1148. [first example of an intronic mutation that affects splicing]
-
Messing A, Brenner M, Feany MB, Nedergaard M, Goldman JE. (2012). Alexander disease. Journal of Neuroscience, 32, 5017-5023. [review] [link to full article]
-
Messing A, Li R, Naidu S, Taylor JP, Silverman L, Flint D, van der Knaap MS, Brenner M. (2012). Archetypal and new families with Alexander disease and novel mutations in GFAP. Archives of Neurology, 69, 208-214. [includes genetics on patients and families originally described by Seil 1968, Duckett 1992, and Schwankhaus 1995] [link to full article]
-
Messing A, Daniels CM, Hagemann TL. (2010). Strategies for treatment in Alexander disease. Neurotherapeutics, 7(4), 507–515. [review] [link to full article]
-
Cho W, Brenner M, Peters N, Messing A. (2010). Drug screening to identify suppressors of GFAP expression. Human Molecular Genetics, 19, 3169-3178
-
Tian R, Wu X, Hagemann TL, Sosunov AA, Messing A, McKhann GM, Goldman JE. (2010). Alexander disease mutant GFAP compromises glutamate transport in astrocytes. Journal of Neuropathology and Experimental Neurology, 69, 335-345
-
Brenner M, Goldman JE, Quinlan RA, Messing A. 2009. (2009). Alexander disease: a genetic disorder of astrocytes. In Astrocytes in Pathophysiology of the Nervous System., ed. V Parpura, PG Haydon, pp. 591-648. Boston: Springer [probably most extensive review of all]
-
Liem RKH and Messing A. (2009). Dysfunctions of neuronal and glial intermediate filaments in disease. Journal of Clinical Investigation, 119, 1814-1824. [contains review of GFAP in blood or CSF as a potential biomarker for various diseases] [link to full article]
-
Cho W, Messing A. (2009). Properties of astrocytes cultured from GFAP-over-expressing and GFAP mutant mice. Experimental Cell Research, 315, 1260-1272.
-
Hagemann TL, Boelens W, Wawrousek E, Messing A. (2009). Suppression of GFAP toxicity by αB-crystallin in mouse models of Alexander disease. Human Molecular Genetics, 18, 1190-1199 [link to full article]
-
Tang G, Yue Z, Talloczy Z, Hagemann T, Cho W, Messing A, Sulzer DL, Goldman JE. (2008). Autophagy induced by Alexander disease-mutant GFAP accumulation is regulated by p38/MAPK and mTOR signaling pathways. Human Molecular Genetics, 17, 1540-1555. [link to full article]
-
Hagemann TL, Connor JX, Messing A. (2006). Alexander disease-associated glial fibrillary acidic protein mutations in mice induce Rosenthal fiber formation and a white matter stress response. Journal of Neuroscience, 26, 11162-11173. [link to full article]
-
Li R, Johnson AB, Salomons GS, van der Knaap MS, Rodriguez D, Boespflug-Tanguy O, Gorospe JR, Goldman JE, Messing A, Brenner M. (2006). Propensity for paternal inheritance of de novo mutations in Alexander disease. Human Genetics, 119, 137-44.
-
Hagemann TL, Gaeta SA, Smith MA, Johnson DA, Johnson JA, Messing A. (2005) Gene expression analysis in mice with elevated glial fibrillary acidic protein and Rosenthal fibers reveals a stress response followed by glial activation and neuronal dysfunction. Human Molecular Genetics, 14, 2443-2458.
-
Li R, Messing A, Goldman JE, Brenner M. (2002). GFAP mutations in Alexander disease. International Journal of Developmental Neuroscience, 20, 259-268.
-
Rodriguez D, Gauthier F, Bertini E, Bugiani M, Brenner M, N’guyen S, Goizet C, Gelot A, Surtees R, Pedespan J-M, Hernandorena X, Troncoso M, Uziel G, Messing A, Ponsot P, Pham-Dinh D, Dautigny A, Boespflug-Tanguy O. (2001). Infantile Alexander disease: spectrum of GFAP mutations and genotype-phenotype correlation. American Journal of Human Genetics, 69, 1134-1140. [see also 69, 1413]
-
Brenner M, Johnson AB, Boespflug-Tanguy O, Rodriguez D, Goldman JE, Messing A. (2001). Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nature Genetics, 27, 117-120. [first description of genetics] [link to full article]
-
Messing A, Head MW, Galles K, Galbreath EJ, Goldman JE, Brenner M. (1998). Fatal encephalopathy with astrocyte inclusions in GFAP transgenic mice. American Journal of Pathology, 152, 391-398.